BIOMAT Database Logo BIOMAT Database Logo

Discovery of a highly potent CECR2 bromodomain inhibitor with 7H-pyrrolo[2,3-d] pyrimidine scaffold. 2022

Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.

Cat eye syndrome chromosome region candidate 2 (CECR2) bromodomain is a module of CECR2-containing remodeling factor (CERF), which is a chromatin remodeling complex correlating with transcriptional control and adjustment of chromatin architecture. Potent chemical probes would be beneficial to gain insights into the biochemical and pharmacological functions of CECR2 BRD. Herein, we report the discovery of a series of CECR2 BRD inhibitors with 7H-pyrrolo[2,3-d] pyrimidine scaffold based on molecular docking model of TP-248 and CECR2 BRD. The most potent inhibitor of this series, DC-CBi-22 with IC50 of 8.0 ± 1.4 nM against CECR2 BRD and selectivity over BPTF BRD up to 24.9-fold. The SARs were detailed according to molecular docking. DC-CBi-22 would serve as a useful chemical probe for the study of CECR2.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D000072417 Protein Domains Discrete protein structural units that may fold independently of the rest of the protein and have their own functions. Peptide Domain,Protein Domain,Domain, Peptide,Domain, Protein,Domains, Peptide,Domains, Protein,Peptide Domains
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
June 2023, European journal of medicinal chemistry,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors.
October 2009, Bioorganic & medicinal chemistry,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
May 2016, Archiv der Pharmazie,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Development of novel nitric oxide production inhibitors based on the 7H-pyrrolo[2,3-d]pyrimidine scaffold.
May 2024, Molecular diversity,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis.
May 2024, Bioorganic chemistry,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Discovery of pyrrolo[2,3-d]pyrimidine-based molecules as a Wee1 inhibitor template.
November 2022, Bioorganic & medicinal chemistry letters,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
X-ray Crystal Structure-Guided Design and Optimization of 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile Scaffold as a Potent and Orally Active Monopolar Spindle 1 Inhibitor.
May 2021, Journal of medicinal chemistry,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
February 2015, Bioorganic & medicinal chemistry,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
November 2021, European journal of medicinal chemistry,
Haibo Lu, and Tian Lu, and Shijia Zu, and Zhe Duan, and Yiman Guang, and Qi Li, and Jingyi Ma, and Dongying Chen, and Bo Li, and Wenchao Lu, and Hualiang Jiang, and Cheng Luo, and Deyong Ye, and Kaixian Chen, and Hua Lin
Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
August 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Copied contents to your clipboard!